Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153

Neoplasma

Volumn 58, Issue 6, 2011, Pages 482-490

  Wu, N ^a   Gu, C ^b   Gu, H ^a   Hu, H ^a   Han, Y ^a   Li, Q ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Troops 95958 People's Liberation Army ^*  (China)

Author keywords

Apoptosis; GADD153; JNK; Lung cancer; Metformin; P38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; ANTIDIABETIC AGENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; ADENOCARCINOMA; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME IMMUNOASSAY; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MAP KINASE KINASE 4; METFORMIN; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR CHOP;

EID: 84857467120     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_06_482     Document Type: Article

References (49)

1. WITTERS LA. The blooming of the French lilac. J Clin Invest 2001; 108:1105-1107.
2. HUNDAL HS, RAMLAL T, REYES R, LEITER LA, KLIP A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992; 131: 1165-1173. doi:10.1210/en.131.3.1165.
3. STUMVOLL M, NURJHAN N, PERRIELLO G, DAILEY G, GERICH JE. Metabolic effects of metformin in non-insulindependent diabetes mellitus. N Engl J Med 1995; 333: 550-554. doi:10.1056/NEJM199508313330903.
4. SHAW RJ, LAMIA KA, VASQUEZ D, KOO SH, BARDEESY N, et al. The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin. Science 2005; 310: 1642-1646. doi:10.1126/science.1120781.
5. EVANS JM, DONNELLY LA, Emslie-Smith AM, ALESSI DR, MORRIS AD, Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305. doi:10.1136/bmj.38415.708634.F7.
6. BOWKER SL, MAJUMDAR SR, VEUGELERS P, JOHNSON JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258. doi:10.2337/diacare.29.02.06.dc05-1558.
7. ANISIMOV VN, BERSTEIN LM, EGORMIN PA, PISKUNOVA TS, POPOVICH IG, et al. Effect of metformin on life span and on the development of spontaneousmammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40: 685-693. doi:10.1016/j.exger.2005.07.007.
8. BUZZAI M, JONES RG, AMARAVADI RK, LUM JJ, DEBERARDINIS RJ, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-6752. doi:10.1158/0008-5472.CAN-06-4447.
9. GOTLIEB WH, SAUMET J, BEAUCHAMP MC, GU J, LAU S, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110: 246-250. doi:10.1016/j.ygyno.2008.04.008.
10. DOWLING RJ, ZAKIKHANI M, FANTUS IG, POLLAK M, SONENBERG N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67: 10804-10812. doi:10.1158/0008-5472.CAN-07-2310.
11. BEN SAHRA I, LAURENT K, LOUBAT A, Giorgettiperaldi S, COLOSETTI P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586. doi:10.1038/sj.onc.1211024.
12. ZAKIKHANI M, DOWLING R, FANTUS IG, SONENBERG N, POLLAK M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273. doi:10.1158/0008-5472.CAN-06-1500.
13. FRYER LG, Parbu-Patel A, CARLING D. The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226-25232. doi:10.1074/jbc.M202489200.
14. HAWLEY SA, GADALLA AE, OLSEN GS, HARDIE DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002; 51: 2420-2425. doi:10.2337/diabetes.51.8.2420.
15. ZHOU G, MYERS R, LI Y, CHEN Y, SHEN X, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
16. BOLSTER DR, CROZIER SJ, KIMBALL SR, JEFFERSON LS. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J Biol Chem 2002; 277: 23977-23980. doi:10.1074/jbc.C200171200.
17. HADAD SM, FLEMING S, Thompson AM. Targeting AMPK: A new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 2008; 67: 1-7. doi:10.1016/j.critrevonc.2008.01.007.
18. MOTOSHIMA H, GOLDSTEIN BJ, IGATA M, ARAKI E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574: 63-71. doi:10.1113/jphysiol.2006.108324.
19. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. doi:10.3322/canjclin.57.1.43.
20. ISAKOVIC A, HARHAJI L, STEVANOVIC D, MARKOVIC Z, SUMARAC-DUMANOVIC M, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007; 64: 1290-1302. doi:10.1007/s00018-007-7080-4.
21. KEFAS BA, CAI Y, LING Z, HEIMBERG H, HUE L, et al. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c- Jun-N-terminal kinase. J Mol Endocrinol 2003; 30: 151-161. doi:10.1677/jme.0.0300151.
22. MEISSE D, VAN DE CASTEELE M, BEAULOYE C, HAINAULT I, KEFAS BA, et al. Sustained activation of AMP- activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 2002; 526: 38-42. doi:10.1016/S0014-5793(02)03110-1.
23. FRIEDMAN AD. GADD153/CHOP, a DNA damage-inducible protein, reduced CAAT/enhancer binding protein activities and increased apoptosis in 32D c13 myeloid cells. Cancer Res 1996; 56: 3250-3256.
24. LUETHY JD, HOLBROOK NJ. Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage. Cancer Res 1992; 52: 5-10.
25. GUYTON KZ, XU Q, HOLBROOK NJ. Induction of the mammalian stress response gene GADD153 by oxidative stress: role of AP-1 element. Biochem. J 1996; 314: 547-554.
26. JOHNSSON A, STRAND C, LOS G. Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts. Cancer Chemother Pharmacol 1999; 43: 348-352. doi:10.1007/s002800050906.
27. OSBORNE CK, BOLAN G, MONACO ME, LIPPMAN ME. Hormone responsive human breast cancer in longterm tissue culture: effect of insulin. Proc Natl Acad Sci U S A 1976; 73: 4536-4540. doi:10.1073/pnas.73.12.4536.
28. BELFIORE A. The role of insulin receptor isoforms andhybridinsulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13: 671-686. doi:10.2174/138161207780249173
29. KIM DG, YOU KR, LIU MJ, CHOI YK, WON YS. GADD153-mediated anticancer effects of N-(4-hydroxyphenyl)-retinamide on human hepatoma cells. J Biol Chem 2002; 277: 38930-38938. doi:10.1074/jbc.M205941200.
30. CARLSON SG, FAWCETT TW, BARTLETT JD, BERNIER M, HOLBROOK NJ. Regulation of the C/EBP-related gene GADD153 by glucose deprivation. Mol Cell Biol 1993; 13: 4736-4744.
31. ABCOUWER SF, SCHWARZ C, MEGUID RA. Glutamine deprivation induces the expression of GADD 45 and GADD 153 primarily by mRNA stabilization. J Biol Chem 1999; 274: 28645-28651.
32. O'reilly MA, STARVERSKY RJ, WATKINS RH, MANISCALCO WM, KENG PC. p53-independent induction of GADD45 and GADD153 in mouse lungs exposed to hypoxia. Am J Physiol Lung Cell Mol Physiol 2000; 278: 552-559.
33. ZINSZNER H, KURODA M, WANG X, BATCHVAROVA N, LIGHTFOOT RT, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998; 12: 982-995. doi:10.1101/gad.12.7.982.
34. Mccullough KD, MARTINDALE JL, KLOTZ LO, AW TY, HOLBROOK NJ. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol Cell Biol 2001; 21: 1249-1259. doi:10.1128/MCB.21.4.1249-1259.2001.
35. LOVAT PE, OLIVERIO S, RANALLI M, CORAZZARI M, RODOLFO C, et al. GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res 2002; 62: 5158-5167.
36. KIM SH, HWANG CI, JUHNN YS, LEE JH, PARK WY, et al. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis 2007; 28: 223-231. doi:10.1093/carcin/bgl227.
37. SATOH T, TOYODA M, HOSHINO H, MONDEN T, YAMADA M, et al. Activation of peroxisome proliferator-activated receptor-stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002; 21: 2171-2180. doi:10.1038/sj.onc.1205279.
38. RON D, HABENER JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992; 6: 439-453. doi:10.1101/gad.6.3.439.
39. NOZAKI S, Sledge Jr GW, Nakshatri H. Repression of GADD153/CHOP by NF-kappaB: a possible cellular defense against endoplasmic reticulum stress-induced cell death. Oncogene 2001; 20: 2178-2185. doi:10.1038/sj.onc.1204292.
40. ZU K, BIHANI T, LIN A, PARK YM, MORI K, et al. Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 2006; 25: 546-554.
41. SARKAR D, SU ZZ, LEBEDEVA IV, SAUANE M, GOPALKRISHNAN RV, et al. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 2002; 99: 10054-10059. doi:10.1073/pnas.152327199.
42. Oh-Hashi K, MARUYAMA W, ISOBE K. Peroxynitrite induces GADD34, 45, and 153 VIA p38 MAPK in human neuroblastoma SH-SY5Y cells. Free Radical Biol Med 2001; 30: 213-221. doi:10.1016/S0891-5849(00)00461-5.
43. KULTZ D, MADHANY S, BURG MB. Hyperosmolality causes growth arrest of murine kidney cells. Induction of GADD45 and GADD153 by osmosensing via stress-activated protein kinase 2. J Biol Chem 1998; 273: 13645-13651. doi:10.1074/jbc.273.22.13645.
44. BRENNER B, KOPPENHOEFER U, WEINSTOCK C, LINDERKAMP O, LANG F, et al. Fasor ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem 1997; 35: 22173-22181. doi:10.1074/jbc.272.35.22173.
45. WANG XZ, RON D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP Kinase. Science 1996; 272: 1347-1349. doi:10.1126/science.272.5266.1347.
46. MAYTIN EV, UBEDA M, LIN JC, HABENER JF. Stress- inducible transcription factor CHOP/GADD153 induces apoptosis in mammalian cells via p38 kinase-dependent and -independent mechanisms. Exp Cell Res 2001; 267: 193-204. doi:10.1006/excr.2001.5248.
47. ALGIRE C, ZAKIKHANI M, BLOUIN MJ, SHUAI JH, POLLAK M. Metformin Attenuates the Stimulatory Effect of a High Energy Diet on in vivo LLC1 Carcinoma Growth. Endocr Relat Cancer 2008;15: 833-839. doi:10.1677/ERC-08-0038.
48. PHOENIX KN, VUMBACA F, CLAFFEY KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2009; 113: 101-111. doi:10.1007/s10549-008-9916-5.
49. STAMBOLIC V, WOODGETT JR, FANTUS IG, PRITCHARD KI, GOODWIN PJ. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treat 2009; 114: 387-389. doi:10.1007/s10549-008-0015-4.